Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy

Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy

Abstract Background This study investigated adherence and associated factors among people with recent injection drug use (IDU) or current opioid agonist therapy (OAT) and compared once-daily to twice-daily hepatitis C virus (HCV) direct-acting antiviral (DAA) therapy. Methods SIMPLIFY and D3FEAT are...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2020-10, Vol.71 (7), p.e115-e124
Hauptverfasser: Cunningham, Evan B, Hajarizadeh, Behzad, Amin, Janaki, Litwin, Alain H, Gane, Edward, Cooper, Curtis, Lacombe, Karine, Hellard, Margaret, Read, Phillip, Powis, Jeff, Dalgard, Olav, Bruneau, Julie, Matthews, Gail V, Feld, Jordan J, Dillon, John F, Shaw, David, Bruggmann, Philip, Conway, Brian, Fraser, Chris, Marks, Philippa, Dore, Gregory J, Grebely, Jason
Format: Artikel
Sprache:eng
Schlagworte:
Analgesics, Opioid - therapeutic use
Anilides - therapeutic use
Antiviral Agents - therapeutic use
Drug Therapy, Combination
Hepacivirus
Hepatitis C - drug therapy
Hepatitis C, Chronic - drug therapy
Humans
Life Sciences
Pharmaceutical Preparations
Ribavirin - therapeutic use
Santé publique et épidémiologie
Sustained Virologic Response
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background This study investigated adherence and associated factors among people with recent injection drug use (IDU) or current opioid agonist therapy (OAT) and compared once-daily to twice-daily hepatitis C virus (HCV) direct-acting antiviral (DAA) therapy. Methods SIMPLIFY and D3FEAT are international, multicenter studies that recruited participants with recent IDU (previous 6 months; SIMPLIFY, D3FEAT) or current OAT (D3FEAT) between March 2016 and February 2017 in 8 countries. Participants received sofosbuvir/velpatasvir (once daily; SIMPLIFY) or paritaprevir/ritonavir/ombitasvir, dasabuvir (twice daily) ± ribavirin (D3FEAT) for 12 weeks administered in electronic blister packs. We evaluated overall adherence (proportion of prescribed doses taken) and nonadherence (
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciz1089